Aprogen pharmaceuticals,Inc. (003060.KS)
KRW 704.0
(-4.22%)
KRW 704.0
(-4.22%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 170.94 Billion KRW | 53.82% |
| 2022 | 111.12 Billion KRW | 440.96% |
| 2021 | -32.59 Billion KRW | 47.28% |
| 2020 | -61.82 Billion KRW | -133.88% |
| 2019 | -26.43 Billion KRW | -261.38% |
| 2018 | 16.37 Billion KRW | -41.22% |
| 2017 | 27.86 Billion KRW | 157.43% |
| 2016 | 10.82 Billion KRW | 216.83% |
| 2015 | -9.26 Billion KRW | -296.11% |
| 2014 | 4.72 Billion KRW | 165.0% |
| 2013 | -7.26 Billion KRW | -1557.6% |
| 2012 | -438.5 Million KRW | -102.34% |
| 2011 | 18.77 Billion KRW | -5.06% |
| 2010 | 19.77 Billion KRW | -8.15% |
| 2009 | 21.52 Billion KRW | 461.92% |
| 2008 | 3.83 Billion KRW | -73.77% |
| 2007 | 14.6 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 142.88 Billion KRW | -18.05% |
| 2024 Q1 | 174.35 Billion KRW | 2.0% |
| 2023 Q3 | 130.89 Billion KRW | 55.6% |
| 2023 Q2 | 84.12 Billion KRW | -32.63% |
| 2023 FY | 170.94 Billion KRW | 53.82% |
| 2023 Q1 | 124.86 Billion KRW | 12.36% |
| 2023 Q4 | 170.94 Billion KRW | 30.6% |
| 2022 Q1 | -14.37 Billion KRW | 55.89% |
| 2022 FY | 111.12 Billion KRW | 440.96% |
| 2022 Q4 | 111.12 Billion KRW | 2330.9% |
| 2022 Q3 | -4.98 Billion KRW | 93.01% |
| 2022 Q2 | -71.26 Billion KRW | -395.71% |
| 2021 FY | -32.59 Billion KRW | 47.28% |
| 2021 Q4 | -32.59 Billion KRW | 30.8% |
| 2021 Q1 | -37.79 Billion KRW | 38.87% |
| 2021 Q2 | -61.96 Billion KRW | -63.98% |
| 2021 Q3 | -47.09 Billion KRW | 24.0% |
| 2020 FY | -61.82 Billion KRW | -133.88% |
| 2020 Q4 | -61.82 Billion KRW | 19.59% |
| 2020 Q3 | -76.88 Billion KRW | -9.06% |
| 2020 Q1 | -37.28 Billion KRW | -41.07% |
| 2020 Q2 | -70.49 Billion KRW | -89.05% |
| 2019 Q2 | 25.78 Billion KRW | 3.07% |
| 2019 Q4 | -26.43 Billion KRW | 3.52% |
| 2019 FY | -26.43 Billion KRW | -261.38% |
| 2019 Q1 | 25.01 Billion KRW | 52.74% |
| 2019 Q3 | -27.39 Billion KRW | -206.25% |
| 2018 Q2 | 5.46 Billion KRW | -82.6% |
| 2018 Q3 | 5.81 Billion KRW | 6.38% |
| 2018 FY | 16.37 Billion KRW | -41.22% |
| 2018 Q4 | 16.37 Billion KRW | 181.54% |
| 2018 Q1 | 31.42 Billion KRW | 12.79% |
| 2017 Q4 | 27.86 Billion KRW | -10.36% |
| 2017 FY | 27.86 Billion KRW | 157.43% |
| 2017 Q3 | 31.08 Billion KRW | 39.88% |
| 2017 Q2 | 22.22 Billion KRW | 18.62% |
| 2017 Q1 | 18.73 Billion KRW | 73.07% |
| 2016 FY | 10.82 Billion KRW | 216.83% |
| 2016 Q2 | 1.2 Billion KRW | 106.96% |
| 2016 Q3 | 2.12 Billion KRW | 76.73% |
| 2016 Q4 | 10.82 Billion KRW | 408.51% |
| 2016 Q1 | -17.3 Billion KRW | -86.79% |
| 2015 Q3 | -14.71 Billion KRW | -8.67% |
| 2015 Q4 | -9.26 Billion KRW | 37.03% |
| 2015 Q1 | -3.4 Billion KRW | -172.12% |
| 2015 Q2 | -13.54 Billion KRW | -297.36% |
| 2015 FY | -9.26 Billion KRW | -296.11% |
| 2014 Q2 | 5.77 Billion KRW | 65.67% |
| 2014 Q1 | 3.48 Billion KRW | 147.96% |
| 2014 FY | 4.72 Billion KRW | 165.0% |
| 2014 Q4 | 4.72 Billion KRW | 10.97% |
| 2014 Q3 | 4.25 Billion KRW | -26.28% |
| 2013 Q4 | -7.26 Billion KRW | -222.95% |
| 2013 FY | -7.26 Billion KRW | -1557.6% |
| 2013 Q3 | -2.25 Billion KRW | -10.07% |
| 2013 Q2 | -2.04 Billion KRW | 75.59% |
| 2013 Q1 | -8.37 Billion KRW | -1810.13% |
| 2012 FY | -438.5 Million KRW | -102.34% |
| 2012 Q4 | -438.5 Million KRW | 0.0% |
| 2012 Q1 | 15.21 Billion KRW | 0.0% |
| 2011 Q1 | 16.64 Billion KRW | 0.0% |
| 2011 FY | 18.77 Billion KRW | -5.06% |
| 2011 Q3 | 26.32 Billion KRW | 52.99% |
| 2011 Q2 | 17.2 Billion KRW | 3.41% |
| 2010 Q1 | 18.3 Billion KRW | 12.26% |
| 2010 FY | 19.77 Billion KRW | -8.15% |
| 2010 Q2 | 8.91 Billion KRW | -51.31% |
| 2009 Q4 | 16.3 Billion KRW | 0.0% |
| 2009 FY | 21.52 Billion KRW | 461.92% |
| 2009 Q2 | 13.38 Billion KRW | 283.01% |
| 2009 Q1 | 3.49 Billion KRW | 2.38% |
| 2008 FY | 3.83 Billion KRW | -73.77% |
| 2008 Q2 | 8.31 Billion KRW | 5.57% |
| 2008 Q1 | 7.87 Billion KRW | -53.72% |
| 2008 Q4 | 3.41 Billion KRW | 0.0% |
| 2007 Q1 | 8.64 Billion KRW | 0.0% |
| 2007 Q2 | 8.74 Billion KRW | 1.15% |
| 2007 FY | 14.6 Billion KRW | 0.0% |
| 2007 Q4 | 17.02 Billion KRW | 16.61% |
| 2007 Q3 | 14.6 Billion KRW | 66.92% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1842.044% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 70.116% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 45.012% |
| HANDOK Inc. | 283.45 Billion KRW | 39.693% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | -751.644% |
| Yuhan Corporation | -69.18 Billion KRW | 347.077% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 11.862% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 4737.878% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 66.992% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 627.084% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -125.893% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | -364.05% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | -107.154% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | -580.822% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1842.044% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 206.942% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 14.931% |
| JW Holdings Corporation | 480.68 Billion KRW | 64.438% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | -3.865% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -145344.98% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -10.735% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -7170.115% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | -643.186% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 2.303% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | -228.898% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1842.044% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | -7.989% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 52.274% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -10.735% |
| Yuhan Corporation | -69.18 Billion KRW | 347.077% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | -25.702% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | -186.461% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 60.167% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -10.735% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | -47.065% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -940.746% |
| CKD Bio Corp. | 143.29 Billion KRW | -19.294% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | -47.28% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 810.438% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 482.133% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -7170.115% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 59.573% |
| Boryung Corporation | 187.72 Billion KRW | 8.941% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 337.95% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -125.893% |
| JW Lifescience Corporation | 26.09 Billion KRW | -555.19% |